BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price upped by UBS Group from $109.00 to $113.00 in a ...

BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” ...

Adjusted EPS of $0.92 topped estimates of $0.53. Revenue climbed to $747 million, beating the forecasted $712 million. Net ...

BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...

The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with CAMP4 Therapeutics. The partners are using CAMP4’s regulatory RNA platform ...

Scotiabank raised the firm’s price target on BioMarin (BMRN) to $80 from $78 and keeps a Sector Perform rating on the shares. The firm is raising its price target on the stock following a Q4 Voxzogo ...

Citi raised the firm’s price target on BioMarin (BMRN) to $82 from $81 and keeps a Neutral rating on the shares. The company reported a Q4 ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents. The company reported sales of $747 ...

Piper Sandler raised the firm’s price target on BioMarin (BMRN) to $126 from $122 and keeps an Overweight rating on the shares following a Q4 ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...